Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.83 |
| ▸ | FBP1 | P09467 | 2/20 | 0.83 |
| ▸ | KDR | P35968 | 2/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 1/20 | 0.83 |
| ▸ | INSR | P06213 | 1/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | FLT4 | P35916 | 1/20 | 0.83 |
| ▸ | CLK1 | P49759 | 1/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.83 |
| ▸ | TEK | Q02763 | 1/20 | 0.83 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362232 | 1.00 | EGFR (0.83) | EGFRFBP1KDRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL28101874 | 0.99 | EGFR (0.81) | EGFRFBP1KDRERBB2AURKA | |
| Water SCHEMBL28549003 | 0.99 | EGFR (0.81) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL30505605 | 0.91 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL2099106 | 0.91 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.90 | EGFR (0.98) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL26637 | 0.89 | FBP1 (0.84) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL30912752 | 0.89 | FBP1 (0.84) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL6994526 | 0.89 | EGFR (0.69) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL24979 | 0.88 | EGFR (0.68) | EGFRFBP1KDRERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850248-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117209436-A | Preparation method of dacatinib key intermediate | 江苏海洋大学 | 2023-12-12 | — | — | CN | claimed |
| CN-115850248-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-112707869-B | Dacotinib impurity and preparation method thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113979954-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113861120-A | Preparation method of dacomitinib | 湖南南新制药股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-112707869-A | Dacotinib impurity and preparation method thereof | 扬子江药业集团有限公司 | 2021-04-27 | — | — | CN | claimed |
| EP-1746999-B1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER LAMBERT CO (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110262877-A1 | HEAT TREATMENT APPARATUS | IHI CORPORATION (JP) | 2011-10-27 | — | — | US | claimed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | claimed |
| JP-4205757-B2 | — | — | 2009-01-07 | — | — | JP | claimed |
| JP-2007536368-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| CN-117209436-B | Preparation method of dacatinib key intermediate | 江苏海洋大学 | 2025-10-17 | — | — | CN | disclosed |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | JIANGSU CONCORD BIOTECHNOLOGY CO., LTD (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | EGFR 41/4885FBP1 4696/4885KDR 503/4885 |
| US-12435045-B2 | Tyrosine kinase inhibitors and pharmaceutical application thereof | SRC, ABL1, ERBB2 | EGFR 9/4885FBP1 2523/4885KDR 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.